Arbutus Biopharma Corporation

NasdaqGS:ABUS Stock Report

Market Cap: US$619.6m

Arbutus Biopharma Future Growth

Future criteria checks 2/6

Arbutus Biopharma is forecast to grow earnings and revenue by 28.6% and 51.8% per annum respectively while EPS is expected to grow by 28% per annum.

Key information

28.6%

Earnings growth rate

28.0%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate51.8%
Future return on equityn/a
Analyst coverage

Low

Last updated20 Nov 2024

Recent future growth updates

Recent updates

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 05

Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

May 23
Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

Moderna Investors Should Beware Patent-Dispute Fallout

Apr 23

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

Apr 10

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24
Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11
Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11
Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08
Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11
We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Earnings and Revenue Growth Forecasts

NasdaqGS:ABUS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20279-37N/AN/A1
12/31/20268-81N/AN/A1
12/31/20255-69N/AN/A5
12/31/20246-73N/AN/A5
9/30/20247-77-72-72N/A
6/30/202410-77-73-73N/A
3/31/202413-74-79-78N/A
12/31/202318-73-87-86N/A
9/30/202322-75-87-86N/A
6/30/202324-73-84-83N/A
3/31/202333-70-84-83N/A
12/31/202239-69-36-35N/A
9/30/202236-69-38-38N/A
6/30/202233-76-36-35N/A
3/31/202221-85-30-29N/A
12/31/202111-88-68-68N/A
9/30/202110-87-64-63N/A
6/30/20218-84-60-59N/A
3/31/20218-79-54-54N/A
12/31/20207-76-52-51N/A
9/30/20206-83-50-50N/A
6/30/20208-147-61-61N/A
3/31/20207-156-70-70N/A
12/31/20196-165-72-71N/A
9/30/20196-158-75-75N/A
6/30/20195-100-65-64N/A
3/31/20195-73-65-64N/A
12/31/20186-67-69-68N/A
9/30/20187-83-62-61N/A
6/30/201812-68N/A-64N/A
3/31/201812-86N/A-51N/A
12/31/201711-85N/A-49N/A
9/30/20178-267N/A-53N/A
6/30/20172-275N/A-52N/A
3/31/20171-387N/A-64N/A
12/31/20161-384N/A-58N/A
9/30/201614-171N/A-60N/A
6/30/201618-180N/A-47N/A
3/31/201621-65N/A-48N/A
12/31/201523-63N/A-56N/A
9/30/201517-62N/A-45N/A
6/30/201517-42N/A-49N/A
3/31/201515-33N/A-39N/A
12/31/201415-39N/A-12N/A
9/30/201418-35N/A-3N/A
6/30/201417-33N/A0N/A
3/31/201418-30N/A5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABUS's revenue (51.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: ABUS's revenue (51.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABUS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 09:35
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arbutus Biopharma Corporation is covered by 27 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Brian SkorneyBaird
David MartinBloom Burton & Co.